Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0849 • ACR Convergence 2025
Mortality and Major Adverse Cardiac Events (MACE) with GLP-1 Receptor Agonists in Psoriatic Arthritis
Nanuka Tsibadze¹, Irakli Tskhakaia¹ and Irene Tan², ¹Jefferson Health - Einstein, Philadelphia, PA, ²Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Glucagon-like-peptide-1 receptor agonists (GLP-1 RAs) are the novel drug class that has gained widespread attention for its cardiovascular, renal and weight loss benefits in…
Abstract Number: 0474 • ACR Convergence 2025
Real-World Experience of Janus Kinase Inhibitors; Retention and Factors Associated with Discontinuation
Joseph Nathan¹, Bayram Farisogullari², Nicholas Jones³, Mohammad Ayoub³, James Brown³, Sarah Levy³, James Brader⁴, Ayse Ersoy⁴, Blossom Israni⁴, Mark Lloyd⁴, Afzal Latheef⁵, Diane Hill⁵, Amybel Taylor⁶, Darshani Arachchige⁶, Hlaing Chitsu⁶, Helen Linklater⁶, Kunal Lather⁷, Luke Gompels⁷, Eman Elfar⁸, Ritu Malaiya⁸, Pedro Machado⁹ and Patrick Kiely¹⁰, ¹St George's Hospital, London, United Kingdom, ²University College London, London, ³Croydon Health Services NHS Trust, Croydon, England, United Kingdom, ⁴Frimley Health NHS Foundation Trust, Frimley, England, United Kingdom, ⁵St George's University Hospitals NHS Foundation Trust, London, England, United Kingdom, ⁶Surrey and Sussex Healthcare NHS Trust, Redhill, England, United Kingdom, ⁷Somerset NHS Foundation Trust, Taunton, England, United Kingdom, ⁸Epsom and St Helier University Hospitals NHS Trust, Carshalton, England, United Kingdom, ⁹Department of Rheumatology, University College London, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ¹⁰St George's University Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: The use of Janus Kinase inhibitors (JAKi) to treat RA and PsA in a real-world setting has not been well described. Our aim was…
Abstract Number: 0042 • ACR Convergence 2025
Serum Proteomic Analysis of Cellular Immune Clusters in Psoriatic Arthritis
Steven Dang¹, Xianwei Li², Sydney Thib³, Darshini Ganatra⁴, liqun Diao⁵, Igor Jurisica⁶, Vinod Chandran⁷ and Lihi Eder⁸, ¹Institute of Medical Science, University of Toronto, Toronto, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Canada, ³Women’s College Research Institute, Toronto, Canada, ⁴Gladman Krembil Psoriatic Arthritis Research Program; Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Canada, ⁵Department of Statistics and Actuarial Science, University of Waterloo, Toronto, Canada, ⁶University Health Network, Toronto, Canada, ⁷Division of Rheumatology, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, and Gladman Krembil Psoriatic Arthritis Research Program, Krembil Research Institute, University Health Network, Toronto, Canada, ⁸University of Toronto, Toronto, ON, Canada
Background/Purpose: Our recent study characterized immune endotypes in psoriatic arthritis (PsA) patients using mass cytometry of peripheral blood1. We identified an endotype characterized by high…
Abstract Number: 2687 • ACR Convergence 2025
Glucagon-like peptide-1 receptor agonists therapy is associated in improvement in psoriatic arthritis-related and metabolic outcomes: A retrospective analysis of two cohorts
Lihi Eder¹, Uma Scher², Kyra Chen³, Alexandra L. Rice³, Sydney Thib⁴ and Rebecca Haberman⁵, ¹University of Toronto, Toronto, ON, Canada, ²NYU School of Medicine, Scarsdale, NY, ³NYU Grossman School of Medicine and NYU Langone Health Psoriatic Arthritis Center, New York, ⁴Women's College Research Institute, Women's College Hospital, Toronto, Canada, ⁵NYU Langone Health, New York, NY
Background/Purpose: Obesity is highly prevalent in psoriatic arthritis (PsA) and is associated with reduced therapeutic response, worse disease outcomes, and increased cardiometabolic risk. Glucagon-like peptide-1…
Abstract Number: 2364 • ACR Convergence 2025
Real-World Characteristics and Treatment Patterns of Difficult-to-Treat Psoriatic Arthritis
Milad Heydari-Kamjani¹, Jennifer Murphy² and Marina Magrey³, ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²University Hospitals, Cleveland Medical Center, cleveland, OH, ³Case Western Reserve University School of Medicine/University Hospitals Cleveland, Richfield, OH
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous inflammatory disease with variable clinical presentation and treatment response. A subset of PsA patients are difficult to treat…
Abstract Number: 2325 • ACR Convergence 2025
Association of Galectin-3 and Myocardial Dysfunction in Patients with Psoriatic Arthritis
Natalia Guajardo-Jauregui¹, Iris J. Colunga-Pedraza², Dionicio A. Galarza-Delgado², Jose R Azpiri-Lopez³, Jesus Alberto Cardenas-de la Garza⁴, Diana E. Flores-Alvarado⁵ and Rosa Arvizu-Rivera⁶, ¹Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁵Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Nuevo Leon, Mexico, ⁶Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico
Background/Purpose: Psoriatic arthritis (PsA) is an immune-mediated condition associated with an increased risk of cardiovascular (CV) events due to disease-specific characteristics. Galectin-3 (Gal-3) is a…
Abstract Number: 1959 • ACR Convergence 2025
The development and validation of a Diagnostic Ultrasound Enthesitis Score (DUET) for Psoriatic Arthritis
Lihi Eder¹, Ricardo Acayaba de Toledo², Catherine Bakewell³, Philippe Carron⁴, Basant Elnady⁵, Amir Haddad⁶, Arthur Kavanaugh⁷, Fahmeen J. Afgani⁸, Arnon Katz⁹, Minna Kohler¹⁰, josefina marin¹¹, Nam Nguyen¹², Adrien NZEUSSEU TOUKAP¹³, Ari Polachek¹⁴, Ernesto Rodriguez¹⁵, Marcos Rosemffet¹⁶, Abha Singh¹⁷, Maria S. Stoenoiu¹⁸, Agnes Szentpetery¹⁹, Iliara Tinazzi²⁰, Janeth Yinh²¹, Mu Yang²², Richard Cook²², Gurjit Kaeley²³ and Sibel Aydin²⁴, ¹University of Toronto, Toronto, ON, Canada, ²Centro Integrado de Pesquisas (CIP) do Hospital de Base de São José do Rio Preto, São José do Rio Preto, Brazil, ³Intermountain Healthcare Medical Group, Salt Lake City, ⁴Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁵Research Centre at Al Hada Armed Forces Hospital, Cairo, Egypt, ⁶Carmel Medical Center, Haifa, Israel, ⁷University of California, San Diego, School of Medicine, San Diego, CA, ⁸Women's College Hospital, Toronto, Canada, ⁹GRAPPA, Seattle, ¹⁰Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹¹Hospital Universitario Rey Juan Carlos, Madrid, Spain, ¹²University of Toronto, Toronto, Canada, ¹³Cliniques Universitaires Saint-Luc, St.-Lambrechts-Woluwe, Belgium, ¹⁴Rheumatology Institute of Beilinson Hospital, Petah Tikva, Israel, ¹⁵Florida Medical Clinic, Tampa, ¹⁶Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, ¹⁷Altman Clinical and Translational Research Institute, University of California San Diego, San Diego, CA, ¹⁸Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹⁹Uppsala University Hospital, Djursholm, Sweden, ²⁰Ospedale Sacro Cuore-Don Calabria, Verona, Italy, ²¹Massachusetts General Hospital, Boston, MA, ²²University of Waterloo, Waterloo, Canada, ²³UF COM-J, Ponte Vedra Beach, FL, ²⁴Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: Enthesitis is a key lesion in psoriatic arthritis (PsA). The Diagnostic Ultrasound Enthesitis Tool (DUET) study aimed to develop and validate a novel sonographic…
Abstract Number: 1462 • ACR Convergence 2025
Five-Year Results of Secukinumab on Minimal Disease Activity (MDA) Components and the Impact of Biologic Treatment Status on Effectiveness and Safety in Patients With Psoriatic Arthritis: Real-World Data From the SERENA Study
Uta Kiltz¹, Petros Sfikakis², Andreas Bounas³, Nicola Gullick⁴, Eric LESPESSAILLES⁵, Jan Brandt-Juergens⁶, Rasho Rashkov⁷, Cynthia Vizcaya⁸, Andreas Clemens⁸, Kim Hoyt⁹, Weibin Bao¹⁰ and Karl Gaffney¹¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²NKUA - SCHOOL OF MEDICINE, Athens, Greece, ³‘OLYMPION’, General Clinic of Patra, Patra, Greece, ⁴Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, Coventry, United Kingdom, ⁵University Hospital of Orléans, Orleans, France, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Clinic of Rheumatology, University Hospital St. Ivan Rilski, Sofia, Bulgaria, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹¹Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom
Background/Purpose: Secukinumab has demonstrated long-lasting efficacy and a favorable safety profile across multiple clinical trials and domains of psoriatic disease. Real-world data provides additional valuable…
Abstract Number: 1431 • ACR Convergence 2025
Radiographic Sacroiliitis in Psoriatic Arthritis: Clinical, Laboratory, and Spinal Radiographic Correlates in an Indian Cohort
SUBIN PHILIP¹, RITESH KUMAR MISHRA², RIZWANA NAUSHAD¹, Lovely Kumari³, Vishnu Koneru⁴, Aishwarya Gopal⁵, Christina Mariaselvam⁶, Chengappa Kavadichanda⁷, Ananthakrishnan Ramesh¹, Molly Thabah¹ and VIR SINGH NEGI¹, ¹JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, Puducherry, India, ²JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, Bhubaneswar, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research,PUDUCHERRY, PUDUCHERRY, Puducherry, India, ⁴JIPMER, Hyderabad, Telangana, India, ⁵Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, Puducherry, India, ⁷Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India
Background/Purpose: Axial involvement in psoriatic arthritis (PsA) is variable and influences treatment choices. Data on axial PsA in Indian patients, especially its clinical and radiographic…
Abstract Number: 1098 • ACR Convergence 2025
Tolerability of Apremilast: Gastrointestinal Side Effects Dominate While Cardiac Safety Remains Reassuring
Francisco Arias¹, Omar Hamdan², Asim Khanfar³, Kristel Barturen⁴ and Roa’a Alshajrawi⁵, ¹University of Texas Rio Grande Valley, McAllen, TX, ²University of Jordan, Az-Zarqa, Jordan, ³Rochester General Hospital, Rochester, NY, ⁴Universidad San Martin de Porres, McAllen, TX, ⁵University of Jordan, Amman, 'Amman, Jordan
Background/Purpose: Apremilast, a PDE-4 inhibitor, is commonly indicated for patients with psoriasis as well as Behçet’s disease. Although this medication is generally well tolerated, numerous…
Abstract Number: 0570 • ACR Convergence 2025
Phyto- and Endo-cannabinoids Exhibit Ex Vivo Anti-Inflammatory Effects in Refractory Rheumatic inflammatory/Autoimmune Patients: Toward Personalized Cannabinoid Therapy
Gilad Halpert¹, Eri Govrin¹, Omer Gendelman¹, Abdulla Watad², Yehuda Shoenfeld¹ and Howard Amital¹, ¹Sheba Medical Center, Ramat Gan, Israel, ²Tel Hashomer Medical Center, Ramat Gan, Israel
Background/Purpose: A substantial number of patients with rheumatic inflammatory/autoimmune diseases, do not achieve adequate symptom control with current standard-of-care therapies, including biologics. The endocannabinoid system…
Abstract Number: 0831 • ACR Convergence 2025
Altered expression of CD11c and HLA-DR on monocyte subsets in individuals at risk of rheumatoid and psoriatic arthritis
Klára Prajzlerová¹, Olga Kryštůfková², Hana Hulejová¹, Nora Růžičková², Petra Hánová¹, Jiri Vencovsky³, Ladislav Šenolt², Jiří Štolfa² and Mária Filková², ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ³Institute of Rheumatology, Praha ⁸, Czech Republic
Background/Purpose: Preclinical phases of rheumatoid arthritis (RA), including therapeutic interventions, have been extensively studied. There is a growing focus on individuals at risk for psoriatic…
Abstract Number: 0455 • ACR Convergence 2025
Assessment of Pain Outcomes in Pooled Phase 3 Trials of a Selective, Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients With Active Psoriatic Arthritis
Lihi Eder¹, Philip J. Mease², Vibeke Strand³, Alexis Ogdie⁴, Atul Deodhar⁵, Rebecca Haberman⁶, April Armstrong⁷, Alice B. Gottlieb⁸, David Roberts⁹, Laurie Eliason¹⁰, Stefan Varga¹¹, Eleni Vritzali¹², Janice Li¹¹ and Laure Gossec¹³, ¹University of Toronto, Toronto, ON, Canada, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³Stanford University School of Medicine, Palo Alto CA, Portola Valley, CA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁶NYU Langone Health, New York, NY, ⁷University of California Los Angeles, Los Angeles, CA, USA, Los Angeles, CA, ⁸Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, ⁹Bristol Myers Squibb, Uxbridge, United Kingdom, ¹⁰Bristol Myers Squibb,, Princeton, NJ, ¹¹Bristol Myers Squibb, Princeton, NJ, ¹²Bristol Myers Squibb, Boudry, Switzerland, ¹³Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: Patients rate pain as one of the most important aspects of psoriatic arthritis (PsA). Pain signaling involves a series of cytokines, including those downstream…
Abstract Number: 0586 • ACR Convergence 2025
Immune Checkpoint agonists: A New horizon for treatment of psoriatic arthritis
Siba Raychaudhuri¹, Christine Abria² and Smriti K Raychaudhuri³, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²Sacramento VA Medical Center, Mather, CA, ³Sacramento VA Medical Center, Davis, CA
Background/Purpose: Check point inhibitor PD-1 (programmed death protein 1) is upregulated during T lymphocyte activation and is important for limiting the duration of activation. Thus,…
Abstract Number: 2686 • ACR Convergence 2025
Impact of autoimmunity, disease activity and treatment on the time course of bone density, microstructure and biomechanics in inflammatory arthritis.
Koray Tascilar¹, Alp Temiz¹, Filippo Fagni², Arnd Kleyer³, Louis Schuster¹, Stephan Kemenes¹, Sara Bayat¹, David Simon⁴ and Georg Schett⁵, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, ³Charite Universitätsmedizin Berlin, Erlangen, Bayern, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ⁵Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: RA and PsA follow different pathomechanisms and incur disease-specific erosive and osteoproliferative bone changes. We used data from a large cohort of RA and…

« Previous Page
1
…
3
4
5
6
7
…
93
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].